OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC

OncoC4, Inc. announced that the US FDA has granted Fast Track designation to ONC-392, the company’s next-gen anti-CTLA-4 monoclonal antibody as a single agent for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) who have had disease progression on prior anti-PD-(L)1 therapy.